282 KB36 KB202220252023Murovec, Anikaštevilka:2str. 39-44COBISSID_HOST:166099715ISSN:2820-5006URN:URN:NBN:SI:doc-ZYDAJMVZslFakulteta za farmacijo, ŠSSFDPlaceboDostavni sistemiNanomaterialiRak (medicina)siRNANanodelci kot nosilci siRNA v terapiji raka|In addition to traditional cancer treatment methods, new and less aggressive approaches to the treatment of the disease are needed due to some effects that are effective in the treatment of cancer recurrence. Small interfering RNA (siRNA) represents an urgent alternative option for cancer treatment, as it is less toxic than traditional approaches such as chemotherapy. One of the main advantages of small interfering RNA therapy is the ability to target any gene. The main limitation of siRNA therapy is insufficient uptake into cells, which is reflected in the poor efficacy of the therapy. Poor stability during circulation and suboptimal pharmacokinetics and biodistribution of siRNA in vivo also represent limitations in the therapy or systemic delivery of siRNA. Therefore, it is necessary to complex or conjugate siRNA molecules with a suitable carrier system. Nanoparticles have recently been proven to be optimal carriers for the delivery of siRNA, which is why this field is currently very topical and many researchers are working on it. By using nanoparticles with siRNA, we could successfully overcome the obstacles in siRNA therapy and thus develop a new way of treating cancerPoleg tradicionalnih metod zdravljenja raka so zaradi neželenih učinkov, odpornosti na zdravljenje in ponovnega pojava raka potrebni novi in manj agresivni pristopi za zdravljenje bolezni. Mala interferenčna RNA (siRNA) predstavlja obetavno alternativno možnost za zdravljenje raka, saj je manj toksična od tradicionalnih pristopov, kot je kemoterapija. Ena izmed glavnih prednosti terapij z malo interferenčno RNA je sposobnost ciljanja kateregakoli gena. Glavna omejitev pri terapiji s siRNA je nezadosten privzem v celice, kar se kaže v slabi učinkovitosti terapije. Omejitve pri terapiji oz. sistemski dostavi siRNA predstavljajo še slaba stabilnost med cirkulacijo in neoptimalna farmakokinetika ter biodistribucija siRNA in vivo. Zato je treba molekule siRNA kompleksirati ali konjugirati z ustreznim nosilnim sistemom. Nanodelci so se v zadnjem času izkazali kot optimalni nosilni sistem za dostavo siRNA, zato je to področje trenutno zelo aktualno in se z njim ukvarjajo številni raziskovalci. Z uporabo nanodelcev s siRNA bi tako lahko uspešno premagali ovire pri zdravljenju s siRNA in s tem razvili nov način zdravljenja rakaTEXTznanstveno časopisjejournalsSlovenian National E-content AggregatorNational and University Library of Slovenia